Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 10, 2015 2:56 PM ET


Company Overview of Paratek Pharmaceuticals, Inc.

Company Overview

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planne...

75 Kneeland Street

Boston, MA 02111

United States

29 Employees





Key Executives for Paratek Pharmaceuticals, Inc.

Chairman of the Board and Chief Executive Officer
Age: 57
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Age: 56
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Age: 43
Total Annual Compensation: $10.4K
Vice President of Research and Development
Age: 63
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.

Paratek Pharmaceuticals, Inc. Key Developments

Paratek Pharmaceuticals, Inc. Expands Leadership Team with Two New Hires

Paratek Pharmaceuticals, Inc. has expanded its senior leadership team with two new hires. The company announced that Regina Paglia has joined as Senior Vice President, Human Resources and Stephen Villano, M.D. has joined as Vice President, Clinical and Medical Affairs. Ms. Paglia will be based in Paratek's Boston headquarters. Dr. Villano will be based out of the company's Philadelphia office. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. It's lead compound, omadacycline, is in Phase 3 development. Ms. Paglia previously held the position of Senior Vice President, Human Resources at Myriant Corporation, where she led initiatives aimed at creating an optimal corporate culture for employee recruitment and retention, such as reward systems, benefits, professional development and other policies. In this capacity, Ms. Paglia also designed and introduced a branded Mission and Core Values initiative for the newly appointed CEO to define organizational direction and enhance employee engagement. Prior to her experience at Myriant, Ms. Paglia served as Vice President, Human Resources for Mascoma Corporation. In this role, she focused on strategies to optimize corporate culture and organizational effectiveness, led the CEO search and was responsible for facilitating a successful transition. Ms. Paglia was also Senior Vice President, Human Resources at Sepracor Pharmaceutical, Inc., now Sunovion Pharmaceuticals, where she led HR Organizational initiatives to scale-up for commercialization. With more than 20 years experience in antiviral and anti-infective research, Dr. Villano previously served as Vice President, Clinical Research and Development at ViroPharma, Inc, adding Business Development to his responsibilities in 2011. In this role, Dr. Villano directed R&D activities for the company's anti-infective programs, and was responsible for medical oversight of clinical studies. He was also responsible for the identification and review of early compounds with potential in niche markets or orphan drugs. Prior to his position at ViroPharma, Dr. Villano was Medical Director, Virology, Medical Science & Development at Dupont Pharmaceuticals Company, where he focused on the development of the antiretroviral medication efavirenz.

Paratek Pharmaceuticals, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:30 AM

Paratek Pharmaceuticals, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:30 AM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Evan Loh, President, Chief Medical Officer and Director.

Paratek Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Paratek Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $15,679,000 against $1,881,000 a year ago. Net loss attributable to common stockholders was $15,699,000 or $0.96 per basic and diluted share against $3,007,000 or $41.79 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $26,312,000 against $2,812,000 a year ago. Net loss attributable to common stockholders was $26,332,000 or $1.71 per basic and diluted share against $4,420,000 or $63.32 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
SCD Enterprises, LLC United States
Desert West Marketing Inc United States
LaneLabs USA, Inc. United States
The Lauridsen Group, Inc. United States
Cerep Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Paratek Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at